Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $263.52 +2.29 (+0.88%) Closing price 04:00 PM EasternExtended Trading$263.00 -0.52 (-0.20%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ascendis Pharma A/S Stock (NASDAQ:ASND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$259.48▼$266.3450-Day Range$243.45▼$277.1852-Week Range$186.05▼$282.15Volume443,598 shsAverage Volume500,407 shsMarket Capitalization$16.44 billionP/E Ratio20.44Dividend YieldN/APrice Target$310.00Consensus RatingBuy Company Overview Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments. Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism. The company is also advancing a pipeline of investigational therapies in areas including endocrinology and rare diseases, including programs based on its TransCon CNP and TransCon immunotherapy platforms. Founded in 2007, Ascendis Pharma is headquartered in Copenhagen, Denmark, with U.S. operations in Palo Alto, California. Its products and development activities serve patients in the United States and other international markets, subject to regulatory approvals. The company is led by Jan Mikkelsen, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 88% of companies evaluated by MarketBeat, and ranked 54th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.05, and is based on 2 strong buy ratings, 17 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAscendis Pharma A/S has a consensus price target of $310.00, representing about 17.6% upside from its current price of $263.52.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth72.82% Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow by 72.82% in the coming year, from $5.15 to $8.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is 20.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is 20.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 212.38.Read more about Ascendis Pharma A/S's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.23% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 13.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.88 News SentimentAscendis Pharma A/S has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ascendis Pharma A/S this week, compared to 6 articles on an average week.Search Interest12 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have sold 64.53% more of their company's stock than they have bought. Specifically, they have bought $492,660.00 in company stock and sold $810,570.00 in company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAscendis Pharma A/S has minimal institutional ownership at this time.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Stock News HeadlinesMads Bodenhoff Sells 3,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND) StockSeptember 10 at 5:22 AM | insidertrades.comFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026September 9 at 4:01 PM | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 11 at 1:00 AM | Banyan Hill Publishing (Ad)Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 8 at 4:01 PM | globenewswire.comAscendis Pharma In Focus Ahead Of Infant Achondroplasia Data At ESPE Congress 2026September 8 at 10:15 AM | rttnews.comAscendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026September 7, 2026 | quiverquant.comQAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026September 7, 2026 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Buys 2,000 SharesAugust 19, 2026 | insidertrades.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $213.24 at the beginning of 2026. Since then, ASND shares have increased by 23.6% and is now trading at $263.52. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Friday, August, 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by $0.68. The biotechnology company had revenue of $387.22 million for the quarter, compared to analysts' expectations of $376.75 million. Ascendis Pharma A/S had a trailing twelve-month return on equity of 32.54% and a net margin of 70.99%. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional investors of Ascendis Pharma A/S include Wellington Management Group LLP (2.48%), Frazier Life Sciences Management L.P. (0.36%), Spyglass Capital Management LLC (0.35%) and California State Teachers Retirement System (0.30%). Insiders that own company stock include Scott Thomas Smith, Mads Bodenhoff, Jean Jacques Bienaime and Flemming Steen Jensen. View institutional ownership trends. How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2026Today9/11/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (19m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ASND's financial health is in the Green zone, according to TradeSmith. ASND has been in this zone for over 19 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,189Year Founded2007Price Target and Rating Average Price Target for Ascendis Pharma A/S$310.00 High Price Target$355.00 Low Price Target$255.00 Potential Upside/Downside+17.6%Consensus RatingBuy Rating Score (0-4)3.05 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)$12.89 Trailing P/E Ratio20.44 Forward P/E Ratio51.17 P/E GrowthN/ANet Income-$258 million Net Margins70.99% Pretax Margin8.92% Return on Equity32.54% Return on Assets7.71% Debt Debt-to-Equity Ratio0.27 Current Ratio2.99 Quick Ratio2.32 Sales & Book Value Annual Sales$814.57 million Price / Sales20.18 Cash FlowN/A Price / Cash FlowN/A Book Value($2.97) per share Price / Book-88.73Miscellaneous Outstanding Shares62,380,000Free Float37,426,000Market Cap$16.44 billion OptionableOptionable Beta0.35 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ASND) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
